434 related articles for article (PubMed ID: 18715208)
1. Long-acting insulin analogs versus human insulins.
Garg SK; Naik RG
Diabetes Technol Ther; 2008 Oct; 10(5):331-2. PubMed ID: 18715208
[No Abstract] [Full Text] [Related]
2. Insulin analogs versus human insulin in type 2 diabetes.
Migdalis IN
Diabetes Res Clin Pract; 2011 Aug; 93 Suppl 1():S102-4. PubMed ID: 21864739
[TBL] [Abstract][Full Text] [Related]
3. Cost-effectiveness of insulin detemir compared to NPH insulin for type 1 and type 2 diabetes mellitus in the Canadian payer setting: modeling analysis.
Tunis SL; Minshall ME; Conner C; McCormick JI; Kapor J; Yale JF; Groleau D
Curr Med Res Opin; 2009 May; 25(5):1273-84. PubMed ID: 19366302
[TBL] [Abstract][Full Text] [Related]
4. Beyond the era of NPH insulin--long-acting insulin analogs: chemistry, comparative pharmacology, and clinical application.
Owens DR; Bolli GB
Diabetes Technol Ther; 2008 Oct; 10(5):333-49. PubMed ID: 18715209
[TBL] [Abstract][Full Text] [Related]
5. Therapy conversion to insulin detemir among patients with type 2 diabetes treated with oral agents: a modeling study of cost-effectiveness in the United States.
Valentine WJ; Erny-Albrecht KM; Ray JA; Roze S; Cobden D; Palmer AJ
Adv Ther; 2007; 24(2):273-90. PubMed ID: 17565917
[TBL] [Abstract][Full Text] [Related]
6. Evaluating the cost-effectiveness of therapy conversion to insulin detemir in patients with type 2 diabetes in Germany: a modelling study of long-term clinical and cost outcomes.
Valentine WJ; Goodall G; Aagren M; Nielsen S; Palmer AJ; Erny-Albrecht K
Adv Ther; 2008 Jun; 25(6):567-84. PubMed ID: 18568451
[TBL] [Abstract][Full Text] [Related]
7. Direct healthcare costs of patients with type 2 diabetes using long-acting insulin analogues or NPH insulin in a basal insulin-only regimen.
Gundgaard J; Christensen TE; Thomsen TL
Prim Care Diabetes; 2010 Oct; 4(3):165-72. PubMed ID: 20452847
[TBL] [Abstract][Full Text] [Related]
8. A comparison of insulin use, glycemic control, and health care costs with insulin detemir and insulin glargine in insulin-naive patients with type 2 diabetes.
Borah BJ; Darkow T; Bouchard J; Aagren M; Forma F; Alemayehu B
Clin Ther; 2009 Mar; 31(3):623-31. PubMed ID: 19393853
[TBL] [Abstract][Full Text] [Related]
9. Increased insulin dose requirement of long-acting insulin analogues in obese patients with type 2 diabetes.
Schmid C; Krayenbühl P; Wiesli P
Diabetologia; 2009 Dec; 52(12):2668-9. PubMed ID: 19774359
[No Abstract] [Full Text] [Related]
10. Modelling cost effectiveness of insulin glargine for the treatment of type 1 and 2 diabetes in Canada.
Grima DT; Thompson MF; Sauriol L
Pharmacoeconomics; 2007; 25(3):253-66. PubMed ID: 17335310
[TBL] [Abstract][Full Text] [Related]
11. A cost comparison of long-acting insulin analogs vs NPH insulin-based treatment in patients with type 2 diabetes using routinely collected primary care data from the UK.
Idris I; Gordon J; Tilling C; Vora J
J Med Econ; 2015 Apr; 18(4):273-82. PubMed ID: 25422990
[TBL] [Abstract][Full Text] [Related]
12. Newer insulins in type 2 diabetes.
Gale EA
BMJ; 2012 Sep; 345():e4611. PubMed ID: 22968720
[No Abstract] [Full Text] [Related]
13. Hypoglycemia and insulin treatment.
Febo F; Molinari C; Piatti PM
J Endocrinol Invest; 2011 Oct; 34(9):698-701. PubMed ID: 22156904
[No Abstract] [Full Text] [Related]
14. Modeling the lifetime costs of insulin glargine and insulin detemir in type 1 and type 2 diabetes patients in Canada: a meta-analysis and a cost-minimization analysis.
Guillermin AL; Samyshkin Y; Wright D; Nguyen T; Villeneuve J
J Med Econ; 2011; 14(2):207-16. PubMed ID: 21361858
[TBL] [Abstract][Full Text] [Related]
15. Costs Associated With Using Different Insulin Preparations.
Tylee T; Hirsch IB
JAMA; 2015 Aug; 314(7):665-6. PubMed ID: 26284715
[No Abstract] [Full Text] [Related]
16. Cost-effectiveness and cost-utility of insulin glargine compared with NPH insulin based on a 10-year simulation of long-term complications with the Diabetes Mellitus Model in patients with type 2 diabetes in Switzerland.
Brändle M; Azoulay M; Greiner RA
Int J Clin Pharmacol Ther; 2007 Apr; 45(4):203-20. PubMed ID: 17474539
[TBL] [Abstract][Full Text] [Related]
17. Advances in basal insulin therapy: lessons from current evidence.
Singh AK; Sinha B
J Indian Med Assoc; 2013 Nov; 111(11):735-6, 738-42. PubMed ID: 24968481
[No Abstract] [Full Text] [Related]
18. New Long-Acting Basal Insulins: Does Benefit Outweigh Cost?
Standl E; Owen DR
Diabetes Care; 2016 Aug; 39 Suppl 2():S172-9. PubMed ID: 27440830
[No Abstract] [Full Text] [Related]
19. A patient centred approach to basal insulin choice for the management of type 2 diabetes mellitus.
Kalra S; Gupta Y
J Pak Med Assoc; 2016 Mar; 66(3):360-1. PubMed ID: 26968297
[TBL] [Abstract][Full Text] [Related]
20. [Insulin detemir compared with NPH insulin. No significant differences identified in the studies].
Liedholm H; Linné AB
Lakartidningen; 2006 May 3-9; 103(18):1417, 1419-22, 1424-6. PubMed ID: 16729454
[No Abstract] [Full Text] [Related]
[Next] [New Search]
